IONS Ionis Pharmaceuticals Inc.

64.46
+0.62  (+1%)
Previous Close 63.84
Open 64.23
Price To Book 7.49
Market Cap 9,045,220,193
Shares 140,322,994
Volume 659,199
Short Ratio
Av. Daily Volume 1,495,631

NewsSee all news

  1. Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) A High Quality Stock To Own?
  2. Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting
  3. See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
  4. Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference
  5. Ionis announces appointment of Joan E. Herman to its board of directors

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiation announced October 13, 2017.
IONIS-MAPTRx
Alzheimer's disease
Phase 2b data due 1H 2020.
AKCEA-ANGPTL3-LRx
Rare hyperlipidemias
Phase 2b data due 1H 2020.
AKCEA-APOCIII-LRx
Hyperlipoproteinemia and established cardiovascular disease
First patient enrolled in Phase 3 trial announced January 28, 2019.
IONIS-HTT Rx
Huntington's Disease
Phase 2 data presented at AHA November 2018 - endpoints met.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2b data likely due 2019.
IONIS-FXIRx
End-stage renal disease
CRL issued August 27, 2018.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
Inotersen (IONIS-TTRRx)
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.
Phase 3 data due 2H 2020.
IONIS-SOD1Rx / BIIB067
Amyotrophic lateral sclerosis (ALS)
Phase 2 trial to be initiated early 2019.
IONIS-FB-LRx
Geographic Atrophy (GA)
Phase 1b/2 data likely due 2019.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer
Phase 1/2 data and Phase 3 trial initiation due 2H 2019.
AKCEA-TTR-LRx
hATTR Amyloidosis
Phase 2 data likely due 2019.
IONIS-HBV-rx
Hepatitis B virus (HBV)
Phase 2 data likely due 2019.
IONIS-GHR-LRx
Acromegaly

Latest News

  1. Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) A High Quality Stock To Own?
  2. Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting
  3. See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
  4. Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference
  5. Ionis announces appointment of Joan E. Herman to its board of directors
  6. Are Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Paying Above The Intrinsic Value?
  7. Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders
  8. Here's Why Mirati Therapeutics Is Jumping Today
  9. Akcea Therapeutics to Present at Upcoming Investor Conferences
  10. Novartis Gene Therapy Crosses The $2 Million Mark — Will Others Follow?
  11. What Is Nektar Therapeutics' New Game Plan?
  12. Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio
  13. Edited Transcript of IONS earnings conference call or presentation 9-May-19 3:30pm GMT
  14. Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock
  15. 7 A-Rated Healthcare Stocks for Industry Expansion
  16. Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
  17. Ionis Pharmaceuticals Is 40% of the Way There
  18. Ionis Pharmaceuticals, Inc. (IONS) Q1 2019 Earnings Call Transcript